ABSTRACT

A compound of formula I,



I

wherein NRR_1 is attached at the 5- or 6-position of the furopyridine ring; R is hydrogen, C_1-C_4 alkyl, or COR_2; R_1 is $(CH_2)_nAr$, $CH_2CH{=}CHAr$, or $CH_2C{\equiv}CAr$; n is 0 to 3; A is N or NO; Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur, any of which may optionally be substituted with one to two substitutents independently selected from: halogen, trifluoromethyl, or C_1-C_4 alkyl; R_2 is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH; OC_1–C_4 alkyl, CO_2R_5, –CN, $–NO_2$, $–NR_3R_4$, or $–CF_3$; R_3, $R_4$and R_5 may be hydrogen, C_1-C_4 alkyl, or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH; OC_1–C_4 alkyl, –CN, $–NO_2$, or $–CF_3$; and enantiomers thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.